Overview

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Camptothecin
Irinotecan
Pemetrexed